Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Conditions:   Carcinoma, Non-Small-Cell Lung;   Colorectal Neoplams;   Endometrial Neoplasms;   Ovarian Neoplasms;   Pancreatic Neoplasms
Interventions:   Drug: LY3537982;   Drug: Abemaciclib;   Drug: Erlotinib;   Drug: Pembrolizumab;   Drug: Temuterkib;   Drug: LY3295668;   Drug: Cetuximab;   Drug: TNO155
Sponsors:   Eli Lilly and Company;   Loxo Oncology, Inc.;   Merck Sharp & Dohme LLC
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 27, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments